Cargando…

PB2512: SAFETY OF CRIZANLIZUMAB IN PATIENTS WITH SICKLE CELL DISEASE: INTEGRATED POST-MARKETING SURVEILLANCE ANALYSIS

Detalles Bibliográficos
Autores principales:	Abboud, Miguel, Kanter, Julie, Marfo, Kwaku, Anthony, Charmaine, Lincy, Jeremie, Nassin, Michele, Joshi, Vikas, Brueckner, Andreas, Keefe, Deborah, Ataga, Kenneth I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428885/ http://dx.doi.org/10.1097/01.HS9.0000976748.46081.72

Ejemplares similares

PB2213: EFFECTIVENESS OF CRIZANLIZUMAB IN REDUCING VASO-OCCLUSIVE CRISIS IN PATIENTS WITH SICKLE CELL DISEASE IN BRAZIL: STUDY PROTOCOL FOR AN OBSERVATIONAL, RETROSPECTIVE, MULTICENTER, NATIONAL STUDY
por: Bueno, C., et al.
Publicado: (2022)

S267: PHARMACOKINETICS/PHARMACODYNAMICS, SAFETY AND EFFICACY OF CRIZANLIZUMAB IN PATIENTS WITH SICKLE CELL DISEASE AGED 12 TO <18 YEARS: 2-YEAR DATA FROM THE PHASE 2 SOLACE-KIDS STUDY
por: Heeney1, Matthew, et al.
Publicado: (2023)

Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease
por: Kanter, Julie, et al.
Publicado: (2022)

5613436 EXPERT CONSENSUS ON THE MANAGEMENT OF INFUSION-RELATED REACTIONS (IRRS) PRESENTING WITH PAIN IN PATIENTS RECEIVING CRIZANLIZUMAB
por: Kanter, J., et al.
Publicado: (2023)

S108: A SYSTEMATIC POST-MARKETING (PM) REVIEW OF RARE INFUSION-RELATED REACTIONS (IRRS) PRESENTING AS PAIN EVENTS DURING OR AFTER CRIZANLIZUMAB INFUSION IN PATIENTS WITH SICKLE CELL DISEASE (SCD)
por: Kanter, J, et al.
Publicado: (2022)

PB2524: TRIAL IN PROGRESS: THE HIBISCUS-KIDS STUDY, A SINGLE-ARM, OPEN-LABEL, PHASE 1/2 STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF ETAVOPIVAT IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE
por: Colombatti, Raffaella, et al.
Publicado: (2023)

PB2528: THE IMPACT OF ZINC SUPPLEMENTATION ON HYPERBILIRUBINEMIA IN SICKLE CELL DISEASE
por: Al Farttoosi, Mohammed
Publicado: (2023)

PB2517: OSTEOMYELITIS IN CHILDREN WITH SICKLE CELL DISEASE: IS MRI PATHOGNOMONIC?
por: Al Lawati, Murtadha, et al.
Publicado: (2023)

UK media reporting of NICE recommendation of crizanlizumab for patients with sickle cell disease
por: Buka, Richard J, et al.
Publicado: (2022)

PB2215: GLOBAL EPIDEMIOLOGY OF SICKLE CELL DISEASE: A SYSTEMATIC LITERATURE REVIEW
por: Colombatti, R., et al.
Publicado: (2022)

PB2513: A RE-AUDIT OF PAIN MANAGEMENT IN SICKLE CELL PAIN CRISES
por: Zhou, Yuhui, et al.
Publicado: (2023)

PB2507: EFFECTS OF TSH ON HEMOGLOBIN S POLYMERIZATION, DEFORMABILITY AND ADHESION ON SICKLE CELL ERYTHROCYTES
por: Reis, Evelyn Mendonça, et al.
Publicado: (2023)

PB2217: SICKLE CELL DISEASE IS A RISK FACTOR FOR THE PROGRESSION AND PROGNOSIS OF COVID-19
por: Goyal, V., et al.
Publicado: (2022)

PB2504: USE OF CONSUMER WEARABLES TO MONITOR AND PREDICT PAIN IN PATIENTS WITH SICKLE CELL DISEASE
por: Vuong, Caroline, et al.
Publicado: (2023)

Real-World Data of Crizanlizumab in Sickle Cell Disease: A Single-Center Analysis
por: Cheplowitz, Halle, et al.
Publicado: (2023)

PB2224: IMPACT OF COVID-19 PANDEMIC ON PATIENTS WITH SICKLE CELL DISEASE: RESULTS FROM THE REAL WORLD ASSESSMENT SURVEY FOR SICKLE CELL DISEASE IN SAUDI (ROARS)
por: Ezzat, H., et al.
Publicado: (2022)

PB2223: COST OF ILLNESS, EPIDEMIOLOGY AND HEALTHCARE RESOURCE UTILIZATION FOR SICKLE CELL DISEASE IN THE GULF “CESGU”
por: Soliman, D., et al.
Publicado: (2022)

PB2225: ENVIRONMENTAL MODIFIERS OF SEVERITY IN CHILDREN WITH SICKLE CELL DISEASE: A FEASIBILITY PILOT STUDY
por: Strouse, J., et al.
Publicado: (2022)

PB2509: RED BLOOD CELL PYRUVATE KINASE PROPERTIES IN SICKLE CELL DISEASE – OF MICE AND MEN
por: Traets, Marissa, et al.
Publicado: (2023)

PB2505: THERAPEUTIC PHLEBOTOMY INSTANTLY AFFECTS BLOOD PARAMETERS AND VISCOCITY IN SICKLE CELL DISEASE PATIENTS
por: Jebali, Amna, et al.
Publicado: (2023)

PB2510: CHARACTERISATION OF SICKLE CELL DISEASE PATIENTS: A PORTUGUESE REAL-WORLD STUDY (ASCEND)
por: Deveza, Maria Manuel, et al.
Publicado: (2023)

PB2514: IMMUNOGENICITY OF ANTI-SARS-COV-2 VACCINES IN PATIENTS WITH SEVERE SICKLE CELL DISEASE
por: Meunier, Benoit, et al.
Publicado: (2023)

PB2508: COMPARING DEFINITIONS OF EPISODES OF VASO-OCCLUSION AS ENDPOINTS IN CLINICAL STUDIES OF SICKLE CELL DISEASE
por: Locatelli, Franco, et al.
Publicado: (2023)

PB2216: VACUOLES APPEAR IN RED BLOOD CELLS TRANSFUSED TO PATIENTS WITH SICKLE CELL DISEASE-RELATED HYPOSPLENISM
por: Dumas, L., et al.
Publicado: (2022)

PB2226: THE ROLE OF COMPLEMENT IN THE IMMUNE RESPONSE OF SICKLE CELL DISEASE PATIENTS AFER COVID-19 VACCINATION
por: Varelas, C., et al.
Publicado: (2022)

PB2221: A SYSTEMATIC LITERATURE REVIEW DESCRIBING PROTECTIVE EFFECTS OF HBF IN SICKLE CELL DISEASE OUTCOMES
por: Mitelman, O., et al.
Publicado: (2022)

PB2526: UMBILICAL CORD BLOOD SCREENING FOR SICKLE CELL DISEASE: A PILOT STUDY IN THE NORTH OF TUNISIA
por: Ouragini, Houyem, et al.
Publicado: (2023)

PB2511: CLINICAL COMPLICATIONS AMONG PATIENTS WITH SICKLE CELL DISEASE WITH RECURRENT VASO-OCCLUSIVE CRISES IN GERMANY
por: Udeze, Chuka, et al.
Publicado: (2023)

Profile of crizanlizumab and its potential in the prevention of pain crises in sickle cell disease: evidence to date
por: Riley, Tanya R, et al.
Publicado: (2019)

Crizanlizumab and comparators for adults with sickle cell disease: a systematic review and network meta-analysis
por: Thom, Howard, et al.
Publicado: (2020)

Recent Advances in Sickle-Cell Disease Therapies: A Review of Voxelotor, Crizanlizumab, and L-glutamine
por: Migotsky, Michael, et al.
Publicado: (2022)

PB2222: THE PROTECTIVE EFFECT OF THE SPLEEN IN SICKLE CELL PATIENTS. A COMPARATIVE STUDY BETWEEN PATIENTS WITH ASPLENIA AND HYPERSPLENISM.
por: Peretz, S., et al.
Publicado: (2022)

PB2522: LIPID PROFILE AND CARDIAC FUNCTIONS IN EGYPTIAN SICKLE CELL DISEASE PATIENTS: A SINGLE CENTER STUDY
por: El Ghamrawy, Mona, et al.
Publicado: (2023)

S268: INTERIM ANALYSIS OF A PHASE 2 TRIAL TO ASSESS THE EFFICACY AND SAFETY OF CRIZANLIZUMAB IN SICKLE CELL DISEASE PATIENTS WITH PRIAPISM (SPARTAN)
por: Anderson, Alan, et al.
Publicado: (2023)

S122: SAFETY AND EFFICACY OF CRIZANLIZUMAB IN ADOLESCENTS WITH SICKLE CELL DISEASE (SCD): INITIAL DATA FROM THE PHASE II, MULTICENTER, OPEN-LABEL SOLACE-KIDS TRIAL
por: Heeney, M, et al.
Publicado: (2022)

PB2227: HEALTH-RELATED QUALITY OF LIFE OVER TIME IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE ADMITTED FOR VASO-OCCLUSIVE CRISIS.
por: Vuong, C., et al.
Publicado: (2022)

PB2231: RATIONALE FOR THE USE OF COMBINATION CHELATION THERAPY IN PATIENTS WITH THALASSEMIA SYNDROMES OR SICKLE CELL ANEMIA: A SYSTEMATIC LITERATURE REVIEW
por: Kattamis, A., et al.
Publicado: (2022)

PB2335: BURDEN OF HOSPITALIZATION, COSTS AND CO-MORBIDITIES IN MEDICAID PATIENTS WITH SICKLE CELL DISEASE (SCD): ANALYSIS OF NATIONAL IN-PATIENT HOSPITAL DATABASE
por: Aggarwal, S., et al.
Publicado: (2022)

PB2219: A REAL-WORLD EXPERIENCE WITH HEALTHCARE RESOURCE UTILIZATION PATTERNS AND RELATED COSTS IN PATIENTS WITH SICKLE CELL DISEASE IN NORTH LEBANON
por: Inati, A., et al.
Publicado: (2022)

PB2527: COMPARING REAL-LIFE VERSUS PREDICTED PARAMETERS WITH OPTIA SPECTRA IN RED BLOOD CELL EXCHANGE IN SICKLE-CELL DISEASE PATIENTS
por: Rumschisky, Pablo Palomo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ond8q441vok00p7mtqs809s556